Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

First Approved AZ’s Med for Type-1 Diabetes

Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes. The European Com...

AZ’s Diabetes Drug Reduces Heart Failure Risk

Farxiga reduced hospitalisation for heart failure regardless of ejection fraction status. Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that Farxi...

AstraZeneca New Med for Rare Disease Got ODD

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung d...

Seres and AstraZeneca in Immuno-Oncology Collaboration

Seres Therapeutics, Inc. announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting the efficac...

EU Advisors Recommend AstraZeneca and Merck’s Tablets

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positi...

Big Pharma Answered for High Prices

U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate...

AZ Drug Reduces MACE in Cases with No Prior Heart Attack

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major...

AZ and MSD’s Drug Delays Pancreatic Cancer Progression

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III POLO trial. Results from the trial ...

NeoTX in Clinical Collaboration with AstraZeneca

astrazeneca
NeoTX Therapeutics, Ltd announced that it has entered into a clinical collaboration with AstraZeneca Group Plc global biologics research and development arm, MedImmune, to support Phase 1b/2 studies i...

Big Pharma to Testify in High Drug Pricing Case

While congressional scrutiny on drug pricing is nothing new, the prospect of some of the pharmaceutical industry's highest-profile CEOs testifying on the issue will make for a must-watch event. In ...

BTD for AstraZeneca’s LRTI Drug

AstraZeneca’s MEDI8897 has secured breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for the prevention of lower respiratory tract infection (LRTI) caused by respir...

EMA Recommended AstraZeneca’s Type I Diabetes Drug

AstraZeneca’s Forxiga (dapagliflozin) has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin i...

AstraZeneca and Aptamer Group to Develop Targeted Kidney Delivery

Biotechnology company Aptamer Group is collaborating with AstraZeneca to develop drug delivery devices targeting the kidney. The two-year project will see AstraZeneca exploring the use of aptamer t...

Sobi Got Rights for AstraZeneca’s Drug

Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of US rights of Synagis (palivizumab) from AstraZeneca in a deal valued at around $1.6bn. The deal also provides Sobi with the right...

Big Pharma’s Experts Go to Biotech

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca. Vo...

Companies with Most FDA Approvals

In 2018, the U.S. Food and Drug Administration (FDA) approved 59 novel drugs, meaning approved new molecular entities (NMEs). The figure for 2017 was 46 novel drugs. The FDA notes, “Each year, CDER a...